Search for: All records

The COVID-19 pandemic demonstrated the public health benefits of reliable and accessible point-of-care (POC) diagnostic tests for viral infections. Despite the rapid development of gold-standard reverse transcription polymerase chain reaction (RT-PCR) assays for SARS-CoV-2 only weeks into the pandemic, global demand created logistical challenges that delayed access to testing for months and helped fuel the spread of COVID-19. Additionally, the extreme sensitivity of RT-PCR had a costly downside as the tests could not differentiate between patients with active infection and those who were no longer infectious but still shedding viral genomes. To address these issues for the future, we propose a novel membrane-based sensor that only detects intact virions. The sensor combines affinity and size based detection on a membrane-based sensor and does not require external power to operate or read. Specifically, the presence of intact virions, but not viral debris, fouls the membrane and triggers a macroscopically visible hydraulic switch after injection of a 40 μL sample with a pipette. The device, which we call the μSiM-DX (microfluidic device featuring a silicon membrane for diagnostics), features a biotin-coated microslit membrane with pores ∼2–3× larger than the intact virus. Streptavidin-conjugated antibody recognizing viral surface proteins are incubated with the sample for ∼1 hour prior to injection into the device, and positive/negative results are obtained within ten seconds of sample injection. Proof-of-principle tests have been performed using preparations of vaccinia virus. After optimizing slit pore sizes and porous membrane area, the fouling-based sensor exhibits 100% specificity and 97% sensitivity for vaccinia virus ( n = 62). Moreover, the dynamic range of the sensor extends at least from 10 5.9 virions per mL to 10 10.4 virions per mL covering the range of mean viral loads in symptomatic COVID-19 patients (10 5.6 –10 7 RNA copies per mL). Forthcoming work will test the ability of our sensor to perform similarly in biological fluids and with SARS-CoV-2, to fully test the potential of a membrane fouling-based sensor to serve as a PCR-free alternative for POC containment efforts in the spread of infectious disease. 

The SARS-CoV-2 pandemic has revealed the need for rapid and inexpensive diagnostic testing to enable population-based screening for active infection. Neither standard diagnostic testing, the detection and measurement of viral RNA (via polymerase chain reaction), or serological testing (via enzyme-linked immunosorbent assay) has the capability to definitively determine active infection. The former due to a lack of ability to distinguish between replicable and inert viral RNA, and the latter due to varying immune responses (ranging from latent to a complete lack of immune response altogether). Despite many companies producing rapid point-of-care (POC) tests, none will address the global scale of testing needed and few help to combat the ever growing issue of testing resource scarcity. Here we discuss our efforts towards the development of a highly manufacturable, microfluidic device that instantly indicates active viral infection status from ~ 20 μL of nasal mucus or phlegm and requires no external power. The device features a biotin functionalized silicon nanomembrane within an acrylic body containing channels and ports for sample introduction and analysis. Virus capture and target confirmation are done using affinity-based capture and size-based occlusion respectively. Modularity of the device is proven with bead and vaccinia virus capture as we work towards testing with both pure SARS-CoV-2 virus and human samples. With success on all fronts, we could achieve an inexpensive POC diagnostic which can determine an individual’s infection status, aiding containment efforts in the current and future pandemics. In addition to direct viral detection, our method can be used as a rapid POC sample preparation tool that limits the application of PCR reagents to those samples which already display viral size and antigen-based positivity through our device. 

We report on a multi‐method sourcing study of 35 mineral pigment artefacts from the Middle Stone Age site of Pinnacle Point 5–6 North (PP5–6 N), dating from about 90–50 ka. The artefacts were analysed and compared with geological samples from seven sources using neutron activation analysis (NAA), and supplemented by data from X‐ray diffraction (XRD) and scanning electron microscopy (SEM). Our preliminary results suggest that the occupants of PP5–6 N likely used at least two local and one currently unidentified and possibly non‐local Fe oxide mineral pigment sources. The mineral pigment artefacts derived from the latter source(s) exhibited manganese (Mn) enrichment with concentrations well above those observed in all sampled source deposits in the study area, suggesting a distinctive formation process. The proportions of the Mn‐enriched mineral pigment artefacts within the PP5–6 N assemblage vary over time, but tend to occur at higher rates in the glacial Marine Isotope Stage (MIS) 4 deposits, which holds potential implications for changes in the use of sources over time, increased mobility or increased exchange during this period.

 

The widely used 0.2/0.22 µm polymer sterile filters were developed for small molecule and protein sterile filtration but are not well‐suited for the production of large nonprotein biological therapeutics, resulting in significant yield loss and production cost increases. Here, we report on the development of membranes with isoporous sub‐0.2 μm rectangular prism pores using silicon micromachining to produce microslit silicon nitride (MSN) membranes. The very high porosity (~33%) and ultrathin (200 nm) nature of the 0.2 µm MSN membranes results in a dramatically different structure than the traditional 0.2/0.22 µm polymer sterile filter, which yielded comparable performance properties (including gas and hydraulic permeance, maximum differential pressure tolerance, nanoparticle sieving/fouling behavior). The results from bacteria retention tests, conducted according to the guidance of regulatory agencies, demonstrated that the 0.2 µm MSN membranes can be effectively used as sterile filters. It is anticipated that the results and technologies presented in this study will find future utility in the production of non‐protein biological therapeutics and in other biological and biomedical applications.

 

Membranes have been used extensively for the purification and separation of biological species. A persistent challenge is the purification of species from concentrated feed solutions such as extracellular vesicles (EVs) from biological fluids. Investigated is a new method to isolate micro‐ and nanoscale species termed tangential flow for analyte capture (TFAC), which is an extension of traditional tangential flow filtration. Initially, EV purification from plasma on ultrathin nanomembranes is compared between both normal flow filtration (NFF) and TFAC. NFF results in rapid formation of a protein cake which completely obscures any captured EVs and also prevents further transport across the membrane. On the other hand, TFAC shows capture of CD63 positive small EVs with minimal contamination. The use of TFAC to capture target species over membrane pores, wash, and then release in a physical process that does not rely upon affinity or chemical interactions is explored. This process is studied with model particles on both ultrathin and conventional thickness membranes. Successful capture and release of model particles is observed using both membranes. Ultrathin nanomembranes show higher efficiency of capture and release with significantly lower pressures indicating that ultrathin nanomembranes are well‐suited for TFAC of delicate nanoscale particles such as EVs.

 

Nanoscale preconfinement of DNA is shown to reduce the variation of passage times through solid‐state nanopores. Preconfinement is previously achieved by forming a femtoliter‐sized cavity capped with a highly porous layer of nanoporous silicon nitride (NPN). This cavity is formed by sealing a NPN nanofilter membrane against a substrate chip using water vapor delamination. Ultimately, this method of fabrication cannot keep a consistent spacing between the filter and solid‐state nanopore due to thermal fluctuations and wrinkles in the membrane, nor can it be fabricated on thousands of individual devices reliably. To overcome these issues, a method is presented to fabricate the femtoliter cavity monolithically, using a selective xenon difluoride (XeF₂) etch to hollow out a polysilicon (poly‐Si) spacer sandwiched between silicon nitride (SiN_x) layers. These monolithically fabricated cavities behave identically to their counterparts formed by vapor delamination, exhibiting similar translocation passage time variation reduction and folding suppression of DNA without requiring extensive manual assembly. The ability to form nanocavity sensors with nanometer‐scale precision and to reliably manufacture them at scale using batch wafer processing techniques will find numerous applications, including motion control of polymers for single‐molecule detection applications, filtering of dirty samples prior to nanopore detection, and simple fabrication of single‐molecule nanobioreactors.

 

Conventional hemodialysis (HD) uses floor‐standing instruments and bulky dialysis cartridges containing ≈2 m²of 10 micrometer thick, tortuous‐path membranes. Portable and wearable HD systems can improve outcomes for patients with end‐stage renal disease by facilitating more frequent, longer dialysis at home, providing more physiological toxin clearance. Developing devices with these benefits requires highly efficient membranes to clear clinically relevant toxins in small formats. Here, the ability of ultrathin (<100 nm) silicon‐nitride‐based membranes to reduce the membrane area required to clear toxins by orders of magnitude is shown. Advanced fabrication methods are introduced that produce nanoporous silicon nitride membranes (NPN‐O) that are two times stronger than the original nanoporous nitride materials (NPN) and feature pore sizes appropriate for middle‐weight serum toxin removal. Single‐pass benchtop studies with NPN‐O (1.4 mm²) demonstrate the extraordinary clearance potential of these membranes (10⁵mL min⁻¹m⁻²), and their intrinsic hemocompatibility. Results of benchtop studies with nanomembranes, and 4 h dialysis of uremic rats, indicate that NPN‐O can reduce the membrane area required for hemodialysis by two orders of magnitude, suggesting the performance and robustness needed to enable small‐format hemodialysis, a milestone in the development of small‐format hemodialysis systems.